市場調查報告書
商品編碼
921255
自行注射器的全球市場:成長,趨勢,及預測Self-injection Device Market - Growth, Trends, and Forecasts (2022 - 2027) |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
自行注射器,是讓患者自己注射藥物的注射器或穿戴式設備。為了定期性注射不用去診療所和醫院,帶給患者和健康護理系統雙方經濟利益,成為自行注射器市場主要成長推動要素之一。還有類風濕性關節炎和癌症等的慢性自體免疫疾病的盛行率增加也是該市場的成長要素。還有佔該市場大幅佔有率的筆型注射器預期進一步擴大。但,由於法規當局認證的嚴格法規,及新興國家對自行注射器的認識缺乏,抑制該市場的成長。
本報告提供全球自行注射器市場的相關調查,市場機會和趨勢,成長及阻礙因素,各產品、使用法、用途、地區的市場分析,競爭情形,主要企業的簡介等資訊。
Self-Injection devices allow patients with chronic diseases to gain control of their treatment schedule and their treatment setting, thus allowing greater independence and freedom in their social, domestic and professional lives. Self-injection may also offer psychological benefits over administration by healthcare professionals, including improved self-esteem. Removing the need to attend a clinic or hospital for regular injections also brings economic benefits to both the patient and the healthcare system. This economic benefit has been the major growth driving factor for this market. Increasing prevalence of chronic autoimmune diseases like rheumatoid arthritis and cancer have also helped the growth as self-injections have application in recovery from these illnesses.
However, stringent regulations for approval from regulatory authorities and lack of awareness of such devices in developing and underdeveloped economies have been restraining the growth of this market.
Pen injectors are used for the subcutaneous delivery of biopharmaceuticals. Although they are also administered by professionals, these are primarily used for self-administration by the patient. First developed to replace vials and syringes for the treatment of diabetes with insulin, such injection devices have been an important part of the drug-delivery devices for a long time.
According to 2018 World Health Organization report, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. This has attributed to rise in global prevalence of diabetes from 4.7% in 1980 to 8.5% in 2014. Moreover, diabetes prevalence has been rising more rapidly in middle- and low-income countries. In 2016, an estimated 1.6 million deaths were directly caused by diabetes. Hence, the worldwide increase in diabetes and the growing pressure on health care costs that pushes toward patient self-injection means that their importance is expected to grow further in the future.
According to the Center for Disease control and prevention (CDC), in 2016, there were an estimated 15.5 million cancer survivors in the United States and this number is expected to increase to 20.3 million by 2026. According to article by Ji Lin et al. published in Population Health Metrics Journal 2018, the projected number and percent of adults with diagnosed diabetes would increase from 22.3 million (9.1%) in 2014 to 39.7 million (13.9%) in 2030, and to 60.6 million (17.9%) in 2060. Also, the number of people with diabetes aged 65 years or older expected to increase from 9.2 million in 2014 to 21.0 million in 2030, and to 35.2 million in 2060. Hence, with increasing prevalence of chronic diseases, the demand for self-injection devices, which are used for treatment or recovery from such diseases, are expected to increase.
Majority of the key player involved in research and manufacturing of self-injection devices are established in developed countries. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rising awareness.